ArticleNature communications2021

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.

Kristin C Hicks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.